SCHEMBL3586705

SCHEMBL3586705

O=C(CN1C(=O)c2ccccc2C1=O)c1cnccn1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
KDM4E B2RXH2 2/20 0.50
TP53 P04637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
GSK3B P49841 1/20 0.49
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 3/20 0.44
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 2/20 0.44
GAA P10253 1/20 0.44
ALOX15 P16050 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802201 0.83 KDM4E (0.57) SMN1; SMN2KDM4ETP53L3MBTL1CA12
SCHEMBL1609678 0.78 SMN1; SMN2 (0.62) SMN1; SMN2KDM4ETP53L3MBTL1CA12
SCHEMBL245402 0.72 MEN1 (0.68) KDM4EALDH1A1MAPTRAB9AMAPK1
SCHEMBL30546567 0.71 GSK3B (0.75) SMN1; SMN2KDM4ETP53L3MBTL1CA12
SCHEMBL543706 0.71 GSK3B (0.75) SMN1; SMN2KDM4ETP53L3MBTL1CA12
SCHEMBL1906596 0.70 GSK3B (0.73) SMN1; SMN2KDM4ETP53L3MBTL1CA12
SCHEMBL18040177 0.70 NAPRT (0.53) SMN1; SMN2KDM4EALDH1A1GAAMEN1
SCHEMBL15143104 0.70 GSK3B (0.58) SMN1; SMN2KDM4ETP53L3MBTL1CA12
SCHEMBL8940040 0.69 CA12 (0.73) KDM4ECA12CA9GSK3BNPC1
Methane SCHEMBL11813940 0.69 GSK3B (0.73) SMN1; SMN2KDM4ETP53L3MBTL1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-06-24 US disclosed
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-06-24 US disclosed
EP-1836188-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES Astex Therapeutics Limited (GB) 2007-09-26 EP disclosed
WO-2006070198-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES CDK1, CDK3, CDK13 SMN1; SMN2 3277/4885KDM4E 990/4885TP53 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.